Skip to main content

Synthesis of PROTAC-Antibody Conjugate for Application in Acute Myeloid Leukemia Therapy

Project description

A novel targeted anti-cancer therapy

Harnessing the power of the immune system to fight cancer is an attractive therapeutic approach. More specifically, conjugating chemotherapeutic drugs to tumour-specific antibodies improves drug delivery and efficiency while minimising side effects. The EU-funded PAC Synthesis project proposes to combine the advantages of protein degradation and antibody targeting into a new therapeutic platform. Scientists will generate conjugates between proteolysis targeting chimeras (PROTAC) and antibodies targeting the myeloid CD33 protein present in acute myeloid leukaemia cells. The employed chemistry ensures conjugate stability in the blood and efficient release of the PROTAC once internalised by cancer cells.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 212 933,76